Press release content from Business Wire. The AP news staff was not involved in its creation.
Lifesciences BC’s 6th Annual ACCESS TO INNOVATION Conference Will Generate Important Conversation Between R&D, Academia, Industry and Government
February 22, 2021 GMT
A compelling and critical conversation will unfold over a two-day period at
February 24 – 25, 2021, will host thought leaders from health research & innovation, academia, industry, and government, as well as key individuals in the life science sector from across the country and abroad. The conversation is about therapeutic innovation, improving health and patient care, while supporting the post COVID-19 economic recovery of British Columbia.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Hormel Foods Announces Executive Appointments
February 22, 2021 GMT
AUSTIN, Minn., Feb. 22, 2021 /PRNewswire/ Hormel Foods Corporation (NYSE: HRL), a global branded food company, today announced the appointments of Jeff Frank to vice president of Grocery Products, leading the strategic integration of the Planters and Corn Nuts brands into Hormel Foods. The Planters and Corn Nuts acquisition was announced on February 11, and is expected to be completed by the summer. Frank currently serves as vice president of marketing for the Foodservice business within Hormel Foods. Additionally, Annemarie Vaupel, currently director of marketing for the Foodservice division, will advance to vice president of marketing for the Foodservice division.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41
February 21, 2021 GMT
SHANGHAI, Feb. 21, 2021 /PRNewswire/ Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of nonalcoholic steatohepatitis (NASH), announces the positive clinical results in overweight and obese subjects for ASC41, a liver-targeted prodrug. The active metabolite of ASC41 is a selective thyroid hormone receptor beta (THR-β) agonist.
Twenty overweight and obese subjects with elevated low density lipoprotein cholesterol (LDL-C) (> 110 mg/dL) were treated with ASC41 10 mg oral tablets or matching placebo tablets once daily in this randomized, double-blind, placebo controlled clinical study. Preliminary data suggested that over 28 days of oral dosing of ASC41, subjects demonstra